STS/ESTS: Advances in Treatment of Resectable Esophageal Cancer

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Hasan Batirel, MD, PhD
Disclosure(s): Medtronic: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Astra Zeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 13, 2022); Johnson & Johnson Ethicon: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Virginia Litle, MD

Presentations

  1. Endoscopic Approaches to Early Stage Esophageal Cancer
    Wayne Hofstetter, IV, MD
     
  2. Advances in Neoadjuvant, Adjuvant, and Immuno Therapies for Esophageal Cancer
    Shanda H. Blackmon, MD, MPH
    Disclosure(s): Medtronic: Speaker (Ongoing); Astra Zeneca: Speaker (Ongoing); Scanlan Inc: Royalties (Ongoing); Steris: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  3. Panel Discussion and Audience Q&A
     
  4. Lymphovascular Invasion Is an Independent Negative Prognostic Factor in Surgically Resected Esophageal Adenocarcinoma: A National Cancer Database Analysis
    Britton B. Donato, MD, MPH, MS
     
  5. Invited Discussant
    Mark Orringer, MD
     
  6. MIE and Robotic Approaches Available in Europe
    Alessandro Bertani, MD PhD
     
  7. Esophagectomy in the Long Run -- Is It Comfortable?
    Hasan F. Batirel, MD, PhD
    Disclosure(s): Medtronic: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Astra Zeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 13, 2022); Johnson & Johnson Ethicon: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  8. Quality of Life after Esophagectomy
    Daniela Molena, MD
    Disclosure(s): Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing); Boston Scientific: Consultant (Terminated, May 31, 2023); Johnson & Johnson Ethicon: Advisory Board (Ongoing), Consultant (Ongoing); Merck: Speaker (Terminated)
     
  9. Panel Discussion and Audience Q&A
Activity summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Activity opens: 
02/01/2024
Activity expires: 
02/15/2027
Cost:
$0.00
Part of: 
2024 STS Annual Meeting Online: General Thoracic Track
Rating: 
0

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Hasan Batirel, MD, PhD
Disclosure(s): Medtronic: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Astra Zeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 13, 2022); Johnson & Johnson Ethicon: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

Virginia Litle, MD

Presentations

  1. Endoscopic Approaches to Early Stage Esophageal Cancer
    Wayne Hofstetter, IV, MD
     
  2. Advances in Neoadjuvant, Adjuvant, and Immuno Therapies for Esophageal Cancer
    Shanda H. Blackmon, MD, MPH
    Disclosure(s): Medtronic: Speaker (Ongoing); Astra Zeneca: Speaker (Ongoing); Scanlan Inc: Royalties (Ongoing); Steris: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  3. Panel Discussion and Audience Q&A
     
  4. Lymphovascular Invasion Is an Independent Negative Prognostic Factor in Surgically Resected Esophageal Adenocarcinoma: A National Cancer Database Analysis
    Britton B. Donato, MD, MPH, MS
     
  5. Invited Discussant
    Mark Orringer, MD
     
  6. MIE and Robotic Approaches Available in Europe
    Alessandro Bertani, MD PhD
     
  7. Esophagectomy in the Long Run -- Is It Comfortable?
    Hasan F. Batirel, MD, PhD
    Disclosure(s): Medtronic: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Astra Zeneca: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, October 13, 2022); Johnson & Johnson Ethicon: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  8. Quality of Life after Esophagectomy
    Daniela Molena, MD
    Disclosure(s): Astra Zeneca: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing); Boston Scientific: Consultant (Terminated, May 31, 2023); Johnson & Johnson Ethicon: Advisory Board (Ongoing), Consultant (Ongoing); Merck: Speaker (Terminated)
     
  9. Panel Discussion and Audience Q&A